Please login to the form below
Exviera
This page shows the latest Exviera news and features for those working in and with pharma, biotech and healthcare.
Gilead gets 'gold' in England's hepatitis C eradication drive
share. Meanwhile AbbVie, which has claimed the bronze status, will supply its pan-genotypic regimen Maviret as well as Viekirax and Exviera.
Latest news
-
Gilead’s hepatitis C sales start to slide – the question is how quickly?
UK. New entrants such as AbbVie's Viekirax (paritaprevir, ombitasvir and ritonavir) and Exviera (dasabuvir) and Merck &Co's Zepatier (elbasvir/grazoprevir) have also played a role, although Gilead maintains that
-
NICE backs three hepatitis C meds, turns down Duchenne drug
NICE issued positive final draft guidance for Gilead's Harvoni (sofosbuvir/ledipasvir), BMS' Daklinza (daclatasvir) and AbbVie's Viekirax (ombitasvir/paritaprevir/ritonavir), with or without Exviera (dasabuvir), making the new drugs
-
First-ever World Hepatitis Summit calls for national programmes
Drugs such as AbbVie's Exviera (dasabuvir), Johnson &Johnson's Olysio (simprevir), Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) have essentially revolutionised treatment, but the latter two
-
NHS England sets up new £190m hep C fund
to AbbVie's Viekirax, a three-drug combination therapy for the disease, and Exviera (dasabuvir), as well as Gilead's hep C pills Sovaldi and Harvoni.
-
J&J signs $1bn deal with Achillion for hepatitis C therapies
of Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir) rise quickly. ... weeks currently required with Harvoni and Viekirax/Exviera.
More from news
Approximately 2 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
AbbVie: New firm, new thinking
However, AbbVie is set to make an impact in 2015 with the launch of its own interferon-free regimen for hepatitis C, a combination of Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- EIT Health and Biogen announce winners of first ‘neurotechprize’
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program
- Scientists discover new approach to treat brain tumours
- UK trial of fourth vaccine dose shows increased protection against COVID-19
- Biogen and Eisai announce FDA submission for early Alzheimer’s treatment
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- Recognising HIV Vaccine Awareness Day
- AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- How scientific storytelling can help Pharma cut through the noise
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Jardiance is first diabetes drug to improve CV outcomes
- Anthem PR appoints new managing director Rebecca Fergusson
- Christian Schade joins Aprea AB
- Assessing the value of interim analyses in clinical trials
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
- Serious about sustainability?
- Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
- How scientific storytelling can help Pharma cut through the noise
- Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...
